105 related articles for article (PubMed ID: 29733987)
21. The Impact of Hospital Teaching Status on Timing of Intervention, Inpatient Morbidity, and Mortality After Surgery for Vertebral Column Fractures with Spinal Cord Injury.
De la Garza Ramos R; Nakhla J; Nasser R; Jada A; Sciubba DM; Kinon MD; Yassari R
World Neurosurg; 2017 Mar; 99():140-144. PubMed ID: 27915066
[TBL] [Abstract][Full Text] [Related]
22. Bone morphogenetic protein (RhBMP-2) as a substitute for iliac crest bone graft in multilevel adult spinal deformity surgery: minimum two-year evaluation of fusion.
Mulconrey DS; Bridwell KH; Flynn J; Cronen GA; Rose PS
Spine (Phila Pa 1976); 2008 Sep; 33(20):2153-9. PubMed ID: 18725869
[TBL] [Abstract][Full Text] [Related]
23. Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2).
Wong DA; Kumar A; Jatana S; Ghiselli G; Wong K
Spine J; 2008; 8(6):1011-8. PubMed ID: 18037352
[TBL] [Abstract][Full Text] [Related]
24. Vertebral osteolysis after posterior interbody lumbar fusion with recombinant human bone morphogenetic protein 2: a report of five cases.
Lewandrowski KU; Nanson C; Calderon R
Spine J; 2007; 7(5):609-14. PubMed ID: 17526434
[TBL] [Abstract][Full Text] [Related]
25. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease--part 1: Large series diagnosis related outcomes and complications with 2- to 9-year follow-up.
Crandall DG; Revella J; Patterson J; Huish E; Chang M; McLemore R
Spine (Phila Pa 1976); 2013 Jun; 38(13):1128-36. PubMed ID: 23370679
[TBL] [Abstract][Full Text] [Related]
26. Synergistic effect of bone morphogenetic proteins 2 and 7 by ex vivo gene therapy in a rat spinal fusion model.
Kaito T; Johnson J; Ellerman J; Tian H; Aydogan M; Chatsrinopkun M; Ngo S; Choi C; Wang JC
J Bone Joint Surg Am; 2013 Sep; 95(17):1612-9. PubMed ID: 24005203
[TBL] [Abstract][Full Text] [Related]
27. Multilevel anterior cervical discectomy and fusion with and without rhBMP-2: a comparison of dysphagia rates and outcomes in 150 patients.
Lu DC; Tumialán LM; Chou D
J Neurosurg Spine; 2013 Jan; 18(1):43-9. PubMed ID: 23157278
[TBL] [Abstract][Full Text] [Related]
28. The effects of lentiviral gene therapy with bone morphogenetic protein-2-producing bone marrow cells on spinal fusion in rats.
Miyazaki M; Sugiyama O; Tow B; Zou J; Morishita Y; Wei F; Napoli A; Sintuu C; Lieberman JR; Wang JC
J Spinal Disord Tech; 2008 Jul; 21(5):372-9. PubMed ID: 18600149
[TBL] [Abstract][Full Text] [Related]
29. Routine use of recombinant human bone morphogenetic protein-2 in posterior fusions of the pediatric spine and incidence of cancer.
Sayama C; Willsey M; Chintagumpala M; Brayton A; Briceño V; Ryan SL; Luerssen TG; Hwang SW; Jea A
J Neurosurg Pediatr; 2015 Jul; 16(1):4-13. PubMed ID: 25860984
[TBL] [Abstract][Full Text] [Related]
30. Variability in rates of arthrodesis procedures for patients with cervical spine injuries with and without associated spinal cord injury.
Daniels AH; Arthur M; Hart RA
J Bone Joint Surg Am; 2007 Feb; 89(2):317-23. PubMed ID: 17272446
[TBL] [Abstract][Full Text] [Related]
31. Blood serum antibody analysis and long-term follow-up of patients treated with recombinant human bone morphogenetic protein-2 in the lumbar spine.
Burkus JK; Gornet MF; Glassman SD; Slosar PJ; Rosner MK; Deckey JE; Nowak J; Hatcher BM
Spine (Phila Pa 1976); 2011 Dec; 36(25):2158-67. PubMed ID: 21325990
[TBL] [Abstract][Full Text] [Related]
32. Bone morphogenetic protein and cancer in spinal fusion: a propensity score-matched analysis.
Mazur-Hart DJ; Yamamoto EA; Yoo J; Orina JN
J Neurosurg Spine; 2023 Dec; 39(6):722-728. PubMed ID: 37657115
[TBL] [Abstract][Full Text] [Related]
33. Inpatient morbidity and mortality after adult spinal deformity surgery in teaching versus nonteaching hospitals.
De la Garza-Ramos R; Jain A; Kebaish KM; Bydon A; Passias PG; Sciubba DM
J Neurosurg Spine; 2016 Jul; 25(1):15-20. PubMed ID: 26943252
[TBL] [Abstract][Full Text] [Related]
34. Costs and readmission rates for the resection of primary and metastatic spinal tumors: a comparative analysis of 181 patients.
Lau D; Chan AK; Theologis AA; Chou D; Mummaneni PV; Burch S; Berven S; Deviren V; Ames C
J Neurosurg Spine; 2016 Sep; 25(3):366-78. PubMed ID: 27129043
[TBL] [Abstract][Full Text] [Related]
35. Incidence and risk factors for dysphagia after anterior cervical fusion.
Singh K; Marquez-Lara A; Nandyala SV; Patel AA; Fineberg SJ
Spine (Phila Pa 1976); 2013 Oct; 38(21):1820-5. PubMed ID: 23873236
[TBL] [Abstract][Full Text] [Related]
36. Complications of rhBMP-2 utilization for posterolateral lumbar fusions requiring reoperation: a single practice, retrospective case series report.
Hoffmann MF; Jones CB; Sietsema DL
Spine J; 2013 Oct; 13(10):1244-52. PubMed ID: 23973099
[TBL] [Abstract][Full Text] [Related]
37. A comprehensive assessment of the risk of bone morphogenetic protein use in spinal fusion surgery and postoperative cancer diagnosis.
Cahill KS; McCormick PC; Levi AD
J Neurosurg Spine; 2015 Jul; 23(1):86-93. PubMed ID: 25860517
[TBL] [Abstract][Full Text] [Related]
38. Current Trends in Recombinant Human Bone Morphogenetic Protein 2 (rhBMP2) Usage for Spinal Fusion Surgery.
Patel HA; Wellington IJ; Lubonja K; Stelzer JW; Antonacci CL; Coskun E; Cote MP; Singh H; Mallozzi SS; Moss IL
Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241110
[TBL] [Abstract][Full Text] [Related]
39. Quantitative study of parathyroid hormone (1-34) and bone morphogenetic protein-2 on spinal fusion outcomes in a rabbit model of lumbar dorsolateral intertransverse process arthrodesis.
Lina IA; Puvanesarajah V; Liauw JA; Lo SF; Santiago-Dieppa DR; Hwang L; Mao A; Bydon A; Wolinsky JP; Sciubba DM; Gokaslan Z; Holmes C; Witham TF
Spine (Phila Pa 1976); 2014 Mar; 39(5):347-55. PubMed ID: 24365898
[TBL] [Abstract][Full Text] [Related]
40. Recombinant human bone morphogenetic protein-2-augmented transforaminal lumbar interbody fusion for the treatment of chronic low back pain secondary to the homogeneous diagnosis of discogenic pain syndrome: two-year outcomes.
Corenman DS; Gillard DM; Dornan GJ; Strauch EL
Spine (Phila Pa 1976); 2013 Sep; 38(20):E1269-77. PubMed ID: 23778368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
